Scientists Breaking the Respiratory Disease Barrier

Leadership

Science

Leadership

A new way of approaching the problem

Aeon Respire's founders spent over 10 years studying and thinking about the roots of inflammatory and obstructive respiratory disease. Through this work they developed a deep appreciation for the importance of structural lung cells as both the instigators and mediators of airway narrowing in disease. This led to the prioritization of a new kind of target that's expressed in both the smooth muscle and the epithelium. They're now bringing their extensive expertise in this area to advance a better approach to achieve long-lasting and robust breathing health for millions.

John Sullivan
Founder, Chief Executive Officer, CTO
Read Bio
Dirk Smith
Founder, VP of Research & Development
Read Bio

Science

Supported by world-class expertise in pulmonary drug development

Aeon Respire is building a strong supporting cast that represent the best in their field. We've sought the top thinkers in airway cell biology, medicinal chemistry, inhalation toxicology and respiratory clinical development. Our operational model is nimble with a deep field of noteworthy expertise.

Donald Kellerman, PharmD
Scientific Advisor
Read Bio
Jeffrey Tepper, PhD, DABT, DSP
Inhalation Toxicology Consultant
Read Bio
Andreas Hochheimer, PhD
Scientific Advisor
Read Bio
Stephen Liggett, MD
Scientific Advisory Board
Read Bio
Longbin Liu, PhD
Scientific Advisor
Read Bio
Stephen Polyak, PhD
Scientific Advisor
Read Bio
Some of our partners

Some of our partners